ED Medications: Cialis, Levitra, Viagra

Increased systemic exposure to vardenafil may result

in an increase in vardenafil-induced adverse effects.

How RedBox Rx can help

Lonafarnib: (Major) Do not use vardenafil orally disintegrating tablets with lonafarnib due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; lonafarnib is a strong CYP3A4 inhibitor. Loperamide: (Moderate) Concomitant use of vardenafil and loperamide may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Loperamide; Simethicone: (Moderate) Concomitant use of vardenafil and loperamide may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Lopinavir; Ritonavir: (Major) Concomitant use of vardenafil and lopinavir increases the risk of QT/QTc prolongation and torsade de pointes (TdP).

What is tadalafil (Cialis®)?

(Major) Do not use vardenafil orally disintegrating tablets with ritonavir due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 72-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; ritonavir is a strong CYP3A4 inhibitor. Coadministration of ritonavir with vardenafil resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax. Concomitant use may increase the risk of levitra price list vardenafil-related adverse effects, such as prolonged erection or QT prolongation. Lorcaserin: (Moderate) Lorcaserin is a serotonin 2C receptor agonist, and priapism is a potential effect of 5-HT2C receptor agonism.

Are Levitra and Cialis the same?

Because there is little experience with the combination of lorcaserin and medications indicated for erectile dysfunction (e.g., phosphodiesterase inhibitors), combined use should be approached with caution. Macimorelin: (Major) Concomitant use of vardenafil and macimorelin increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Maprotiline: (Moderate) Concomitant use of vardenafil and maprotiline may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Mefloquine: (Moderate) Concomitant use of vardenafil and mefloquine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Methadone: (Major) Concomitant use of vardenafil and methadone increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Nifedipine: (Moderate) Nifedipine can have additive hypotensive effects

when administered with phosphodiesterase inhibitors (PDE 5 inhibitors).

The patient should be monitored carefully and the

• Levitra works by blocking PDE5 enzyme, enhancing erectile response.
• Patients should not engage in strenuous activity immediately after taking Levitra.
• It is often prescribed when other ED treatments have failed or are unsuitable.
• Levitra has a rapid onset, with effects usually seen within 30-60 minutes.
• The medication is available in various dosages to tailor treatment.
• Alcohol and high-fat foods can impair the absorption of Levitra.
• Women should not take Levitra as it is not approved for female use.
• Regular follow-up with a healthcare provider helps monitor treatment efficacy.

dosage should be adjusted based on clinical response.

What should I avoid while using Levitra?

Vardenafil is a primary CYP3A4 substrate that is associated with QT prolongation. Both therapeutic and supratherapeutic doses of vardenafil can produce an increase in QTc interval. Lefamulin is a moderate CYP3A4 inhibitor that has a concentration-dependent QTc prolongation effect. Coadministration of vardenafil with another moderate CYP3A4 inhibitor increased the AUC of vardenafil by 4-fold. Lenacapavir: (Major) Do not use vardenafil orally disintegrating tablets with lenacapavir due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets.

Dosage for erectile dysfunction

Vardenafil is primarily metabolized by CYP3A; lenacapavir is a moderate CYP3A inhibitor. Lenvatinib: (Major) Concomitant use of vardenafil and lenvatinib increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Letermovir: (Major) Do not use vardenafil orally disintegrating tablets with letermovir due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; letermovir is a moderate CYP3A4 inhibitor. Leuprolide: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., leuprolide) may increase the risk of QT/QTc prolongation and torsade levitra generic no prescription de pointes (TdP) in some patients.

What is the most effective ED drug?

Consider taking steps to minimize the risk of QT/QTc interval prolongation and TdP, such as avoidance, electrolyte monit oring and repletion, and ECG monitoring, especially in patients with additional risk factors for TdP. Leuprolide; Norethindrone: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., leuprolide) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Levofloxacin: (Moderate) Concomitant use of levofloxacin and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Levoketoconazole: (Contraindicated) Avoid concomitant use of ketoconazole and vardenafil due to an increased risk for QT/QTc prolongation and torsade de pointes (TdP). Lithium: (Moderate) Concomitant use of vardenafil and lithium may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. For example, in patients whose hypertension was controlled with nifedipine, vardenafil

• Levitra's approval has expanded options for men seeking ED treatment.
• It is one of several PDE5 inhibitors designed for erectile enhancement.
• Men should consider potential side effects and interactions before use.
• Levitra can be taken on an as-needed basis, not necessarily daily.
• Proper diagnosis of ED involves a thorough medical examination.
• Persistent ED can be a sign of underlying health issues needing attention.
• Levitra’s pharmacokinetics allow for flexibility in planning for intimacy.
• Always follow prescribed instructions to maximize safety and effectiveness.

produced mean additional supine systolic/diastolic blood pressure reductions of 3 to

Connect globally

Metronidazole: (Moderate) Concomitant use of metronidazole and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Midostaurin: (Major) Concomitant use of vardenafil and midostaurin increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Mifepristone: (Major) Do not use vardenafil orally disintegrating tablets with mifepristone due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A and mifepristone is a strong CYP3A inhibitor. Mirtazapine: (Moderate) Concomitant use of vardenafil and mirtazapine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.

Side Effects:

Mobocertinib: (Major) Concomitant use of mobocertinib and vardenafil increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Moxifloxacin: (Major) Concomitant use of vardenafil and moxifloxacin increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Nefazodone: (Major) Do not use vardenafil orally disintegrating tablets with nefazodone due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; nefazodone is a strong CYP3A4 inhibitor. Nelfinavir: (Major) Do not use vardenafil orally disintegrating tablets with nelfinavir due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets.

Viagra™ Side Effects

Vardenafil is primarily metabolized by CYP3A4/5; nelfinavir is a strong CYP3A4 inhibitor. Netupitant, Fosnetupitant; Palonosetron: (Major) Do not use vardenafil orally disintegrating tablets with netupitant due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; netupitant is a moderate CYP3A4 inhibitor. Nicardipine: (Moderate) Vardenafil is metabolized by hepatic cytochrome P450 3A4 and to a lesser extent CYP2C9. Inhibitors of CYP3A4, such as nicardipine, can reduce vardenafil clearance. 4 mmHg (age group 65 to 69 years) and 5 to 6 mmHg (age group 70 to 80 years) compared to placebo.

• Levitra is approved for the treatment of erectile dysfunction in men over 18.
• It is not recommended for use in women or children.
• The medication is usually taken orally, in tablet form.
• Levitra's effectiveness relies on sexual stimulation to initiate an erection.
• Adverse effects are typically mild but can include dizziness and upset stomach.
• Consult your healthcare provider if you experience prolonged or painful erections.
• Levitra should be used cautiously in men with liver or kidney disease.
• Always disclose your complete medical history to ensure safe use.

Nilotinib: (Major) Avoid the concomitant use of nilotinib with other agents known to prolong the QT interval, such as vardenafil.

Next Steps

Inotuzumab Ozogamicin: (Major) Concomitant use of vardenafil and inotuzumab increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Isavuconazonium: (Major) Do not use vardenafil orally disintegrating tablets with isavuconazonium due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Itraconazole: (Major) Do not use vardenafil orally disintegrating tablets with itraconazole due to increased vardenafil exposure. Vardenafil is primarily metabolized by CYP3A4/5; itraconazole is a strong CYP3A4 inhibitor. If coadministration of itraconazole and vardenafil oral tablets is required, the maximum single vardenafil dose is 5 mg every 24 hours in patients receiving itraconazole 200 mg daily; for patients receiving itraconazole 400 mg daily, the maximum single vardenafil dose is 2.5 mg every 24 hours.

Drug Interactions

In addition, both itraconazole and vardenafil have been associated with QT prolongation; coadministration may increase this risk. Ketoconazole: (Contraindicated) Avoid concomitant use of ketoconazole and vardenafil due to an increased risk for QT/QTc prolongation and torsade de pointes (TdP). Concomitant use may also increase the exposure of vardenafil, further increasing the risk for adverse effects, such as hypotension and syncope. If concomitant use of ketoconazole and vardenafil oral tablets is required, the maximum single vardenafil oral tablet dose is 5 mg every 24 hours for patients receiving ketoconazole 200 mg daily and 2.5 mg every 24 hours for patients receiving ketoconazole 400 mg daily. Do not use vardenafil orally disintegrating tablets (ODTs) with ketoconazole.

Related treatment guides

Coadministration with ketoconazole increased the AUC of vardenafil by 10-fold. Lansoprazole; Amoxicillin; Clarithromycin: (Major) Do not use vardenafil orally disintegrating tablets with clarithromycin due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Lapatinib: (Moderate) Concomitant use of vardenafil and lapatinib may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Lefamulin: (Major) Coadministration of lefamulin tablets is contraindicated with vardenafil due to increased vardenafil exposure which may result in QT prolongation and torsade de pointes (TdP). Avoid use of lefamulin injection with vardenafil; however, if coadministration of lefamulin injection cannot be avoided, ECG monitoring is recommended during treatment. Sudden death and QT prolongation have occurred in patients receiving nilotinib therapy.

• Levitra is a prescription medication used to treat erectile dysfunction in men.
• The active ingredient in Levitra is vardenafil.
• Levitra helps increase blood flow to the penis during sexual activity.
• It is usually taken 25 to 60 minutes before sexual activity.
• The typical starting dose is 10 mg, adjustable based on effectiveness and side effects.
• Levitra should not be used more than once a day.
• Common side effects include headache, flushing, and nasal congestion.
• Levitra is contraindicated with nitrates and certain heart medications.